Medication info
Dapagliflozin Extended-Release Tablets 10/1000 Milligrams

Dapagliflozin Extended-Release Tablets 10/1000 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
Yellow to deep yellow, oval, biconvex extended-release film-coated tablets
Packaging
30 tablets/box [6 tablets/PTP (Alu-Alu) × 5]
Approval status
Active

MFDS item code 202300347 · Approved 2023.01.27 · Insurance code 669908330

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this drug is one tablet of 5mg/500mg or 10mg/500mg once daily. Gradually titrate the dose to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be started at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching to this drug from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood glucose control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used together with diet and exercise to improve blood glucose control in adults with type 2 diabetes. In particular, it enhances glycemic control effects by using dapagliflozin in combination with metformin. Additionally, it is recommended to consult with a specialist regarding the effects of dapagliflozin on the occurrence of cardiovascular events in patients with insufficient glycemic control who have cardiovascular disease or risk factors. This medication helps manage type 2 diabetes and improve blood glucose control.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this drug is one tablet of 5mg/500mg or 10mg/500mg once daily. Gradually titrate the dose to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be started at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching to this drug from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Precautions

This medication is used for the treatment of diabetes and can rarely cause a serious metabolic complication known as lactic acidosis. Lactic acidosis can be life-threatening, so if symptoms appear, you must inform your doctor immediately. Also, when taken with insulin or sulfonylurea medications, the risk of hypoglycemia may increase, so caution is needed. Symptoms of hypoglycemia can include dizziness, cold sweat, and tremors, and you should respond immediately if these symptoms occur. Patients with poor kidney function, especially those with moderately or severely impaired kidney function, should not use this medication, and it should be administered cautiously in states where there is a risk of declining kidney function. This medication should be avoided in the presence of acute conditions that can affect kidney function, such as dehydration, severe infections, cardiovascular issues, acute myocardial infarction, or sepsis. It is safest for women who are pregnant or potentially pregnant, and nursing mothers not to use this medication. Additionally, patients who are allergic to any component of this drug should not be administered this medication. This drug increases urine output which can lower blood pressure, so patients at risk of hypotension or reduced fluid volume should be careful. Elderly patients or those taking diuretics need to be particularly cautious. During treatment, there can be occurrences of genital infections or urinary tract infections, so you should consult your doctor immediately if related symptoms appear. Vitamin B12 deficiency may occur, so it is advisable to check blood levels of vitamin B12 during long-term treatment. Excessive alcohol consumption should be avoided while taking this medication, and it should be suspended for a period before undergoing surgery or iodine contrast imaging tests. In case of overdose, you must visit a healthcare facility immediately for appropriate treatment, and this medication’s safety and efficacy have not been established in children or adolescents. Finally, while this medication generally does not significantly affect driving or machine operation, caution is necessary due to possible dizziness.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased blood urea
  • weight loss
  • ketosis
  • urinary sepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendonitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • muscle weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow to deep yellow, oval, biconvex extended-release film-coated tablets

Package unit

30 tablets/box [6 tablets/PTP (Alu-Alu) × 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.